Clinical study on Shugan Hewei Decoction and mosapride tablets in treating functional dyspepsia with anxiety and depression
-
摘要: 目的 探讨疏肝和胃方结合莫沙必利片对功能性消化不良伴焦虑及抑郁状态的治疗疗效。方法 选取2019年5月—2021年5月收治的128例功能性消化不良伴焦虑及抑郁状态的患者作为研究对象，采用数字随机表法分为对照组和研究组，每组64例。对照组给予枸橼酸莫沙必利分散片，口服，5 mg/次，3次/d; 观察组在对照组基础上给予疏肝和胃方，2组均治疗4周。比较2组治疗后疗效和不良反应，治疗前后按照症状(餐后饱胀、泛酸、嗳气、上腹疼痛)轻重程度对患者症状进行评分，并比较2组治疗前后抑郁(SDS)与焦虑(SAS)量表评分。结果 研究组治疗总有效率显著高于对照组(89.06% vs 73.44%，P< 0.05)。2组治疗后餐后饱胀、早饱、上腹部灼烧感、上腹疼痛症状评分、SDS评分与SAS评分均显著降低(P< 0.05)，其中研究组症状评分、SDS评分和SAS评分显著低于对照组(P< 0.05)。对照组不良反应(头晕、便秘和睡眠障碍)发生率为26.56%，观察组不良反应(头晕、便秘和睡眠障碍)发生率为21.87%，2组比较差异无统计学意义。结论 疏肝和胃方结合莫沙必利片对功能性消化不良伴焦虑及抑郁状态患者具有较好的临床疗效，不良反应发生率低，可以显著改善临床症状，降低患者的焦虑及抑郁评分，改善机体激素调节。Abstract: Objective To explore the therapeutic effect of Shugan Hewei Decoction combined with mosapride tablets on functional dyspepsia with anxiety and depression.Methods A total of 128 patients with functional dyspepsia with anxiety and depression from May 2019 to May 2021 were enrolled. They were divided into control group and study group by digital random grouping method, with 64 cases in each group. Patients in the control group were treated with mosapride citrate dispersible tablets(oral 5 mg/time, 3 times a day). Patients in the study group were treated with Shugan Hewei formula on the basis of the control group. Patients in both groups were treated for 4 weeks. After treatment, the therapeutic effects and adverse events of both groups were compared. The patients' symptoms were scored according to the severity of symptoms(postprandial fullness, pantothenic acid, belching and epigastric pain) before and after treatment. The scores of depression(SDS) and anxiety(SAS) were compared between the two groups before and after treatment.Results The total effective rate of treatment in the study group was significantly higher than that in the control group(89.06% vs 73.44%,P< 0.05). After treatment, postprandial fullness, early satiety, burning sensation of upper abdomen, symptom score of upper abdominal pain, SDS score and SAS score were significantly lower in the two groups(P< 0.05), and the symptom score, SDS score and SAS score in the study group were significantly lower than those in the control group(P< 0.05). The incidence of adverse events such as sleep disturbance, dizziness, and constipation in the control group was 26.56%, and the incidence of adverse events such as sleep disturbance, dizziness, and constipation in the observation group was 21.87%. There was no significant difference in adverse events between the two groups.Conclusion Shugan Hewei Decoction combined with mosapride tablets has an excellent clinical therapeutic effect on patients with functional dyspepsia accompanied by anxiety and depression, and the incidence of adverse events is low. It can significantly improve clinical symptoms, reduce patients' anxiety and depression scoress, and improve hormone regulation.
-
Key words:
- Shugan Hewei Decoction /
- mosapride /
- functional dyspepsia /
- anxiety /
- depression
-
-
表 1 2组临床疗效比较
组别 例数 显效/例(%) 有效/例(%) 无效/例(%) 总有效率/% 对照组 64 20(31.25) 27(42.19) 17(26.56) 73.44 研究组 64 29(45.31) 28(43.75) 8(12.50) 89.061) 与对照组比较，1)P < 0.05。 
下载: 导出CSV
表 2 2组治疗前后症状评分比较
分，X±S 组别 餐后饱胀 早饱 上腹部灼烧感 上腹疼痛 对照组 治疗前 3.42±0.33 3.32±0.28 3.42±0.54 2.80±0.45 治疗后 1.37±0.121) 1.51±0.231) 0.82±0.151) 1.31±0.211) 研究组 治疗前 3.40±0.36 3.43±0.22 3.35±0.46 2.76±0.40 治疗后 0.85±0.201)2) 0.87±0.181)2) 0.34±0.131)2) 0.82±0.321)2) 与同组内治疗前比较，1)P < 0.05;与对照组比较，2)P < 0.05。
下载: 导出CSV
表 3 2组治疗前后焦虑与抑郁评分比较
分，X±S 组别 SAS评分 SDS评分 对照组 治疗前 55.32±4.38 58.49±4.01 治疗后 52.28±3.301) 55.47±2.861) 研究组 治疗前 56.03±4.14 59.33±4.20 治疗后 48.85±5.031)2) 50.66±6.171)2) 与同组内治疗前比较，1)P < 0.05;与对照组比较，2)P < 0.05。
下载: 导出CSV
-
[1] Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia[J]. Lancet, 2020, 396(10263): 1689-1702. doi: 10.1016/S0140-6736(20)30469-4
[2] 欧阳华, 姜红建, 李强. 功能性消化不良的抗抑郁焦虑药物治疗研究[J]. 山西医药杂志, 2019, 48(21): 2634-2635. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYY201921019.htm
[3] Holtmann G, Shah A, Morrison M. Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview[J]. Dig Dis, 2017, 35(Suppl 1): 5-13.
[4] 王凯, 林文, 邹超, 等. 莫沙必利联合黛立新治疗功能性消化不良伴抑郁患者的疗效观察[J]. 当代医学, 2019, 25(3): 64-65. doi: 10.3969/j.issn.1009-4393.2019.03.028
[5] 耿琼梅, 李坤华. 抗抑郁焦虑药佐治功能性消化不良的临床效果[J]. 临床合理用药杂志, 2021, 14(16): 15-17. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202116006.htm
[6] Talley NJ, Locke GR, Saito YA, et al. Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study[J]. Gastroenterology. 2015, 149(2): 340-349. e2. doi: 10.1053/j.gastro.2015.04.020
[7] 王化虹, 刘建湘, 迟雁. 新的功能性胃肠病诊治标准——罗马Ⅲ标准简介[J]. 中国实用内科杂志, 2006, 26(18): 79-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK200618024.htm
[8] 李军祥, 中国中西医结合学会消化系统疾病专业委员会. 功能性消化不良中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2017, 25(12): 889-894. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201712001.htm
[9] 马睿杰, 陈炜吉, 徐霞, 等. 和胃针法治疗失眠伴焦虑状态的随机对照研究[J]. 中华中医药杂志, 2019, 34(2): 404-407. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201902107.htm
[10] Jokelainen J, Timonen M, Keinänen-Kiukaanniemi S, et al. Validation of the Zung self-rating depression scale(SDS)in older adults[J]. Scand J Prim Health Care, 2019, 37(3): 353-357. doi: 10.1080/02813432.2019.1639923
[11] Du LJ, Chen BR, Kim JJ, et al. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis[J]. World J Gastroenterol, 2016, 22(12): 3486-3495. doi: 10.3748/wjg.v22.i12.3486
[12] Mounsey A, Barzin A, Rietz A. Functional Dyspepsia: Evaluation and Management[J]. Am Fam Physician, 2020, 101(2): 84-88.
[13] Pesce M, Cargiolli M, Cassarano S, et al. Diet and functional dyspepsia: Clinical correlates and therapeutic perspectives[J]. World J Gastroenterol, 2020, 26(5): 456-465. doi: 10.3748/wjg.v26.i5.456
[14] 王大海, 肖嘉新. 泮托拉唑联合莫沙必利对胃食管反流病患者生活质量及满意度的影响[J]. 医学理论与实践, 2019, 32(16): 2564-2566. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLL201916033.htm
[15] 方红萍, 陈寿元. 疏肝和胃汤治疗慢性胃炎105例临床观察[J]. 世界最新医学信息文摘, 2019, 19(23): 206-211. https://www.cnki.com.cn/Article/CJFDTOTAL-WMIA201923130.htm
[16] 牟雄军, 明浩, 许乐思, 等. 疏肝和胃汤抗抑郁作用有效物质部位筛选及其对海马内多种神经递质含量影响的研究[J]. 中国中药杂志, 2019, 44(3): 124-132. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY201903012.htm
[17] 张建军, 胡春玲. 中药党参研究的现代进展[J]. 甘肃高师学报, 2017, 22(3): 39-43. https://www.cnki.com.cn/Article/CJFDTOTAL-GSGS201703012.htm
[18] 宫萍, 赵桂年, 尹璐忆, 等. 茯苓治疗胃肠道疾病作用机制研究[J]. 河南中医, 2021, 41(1): 159-162. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY202101038.htm
[19] 张爱华, 郭姗姗. 柴胡的临床运用及药理研究[J]. 中医研究, 2019, 32(4): 7-9. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYJ201904004.htm
-